MCID: SCH014
MIFTS: 57

Schistosomiasis

Categories: Infectious diseases, Rare diseases

Aliases & Classifications for Schistosomiasis

MalaCards integrated aliases for Schistosomiasis:

Name: Schistosomiasis 12 75 53 55 3 44 15 17 72
Katayama Fever 53 72
Bilharzia 53 3
Schistosoma Mansoni Infection 53
Schistosomiasis Mansoni 72
Blood Fluke 53

Classifications:



External Ids:

Disease Ontology 12 DOID:1395
ICD9CM 35 120.8
MeSH 44 D012552
UMLS 72 C0029827 C0036323 C0036330 more

Summaries for Schistosomiasis

NIH Rare Diseases : 53 Schistosomiasis is a disease caused by parasitic worms. Although the worms that cause schistosomiasis are not found in the United States, more than 200 million people are infected worldwide. Infection occurs through contact with contaminated water. The parasite in its infective stages is called a cercaria. It swims freely in open bodies of water. On contact with humans, the parasite burrows into the skin, matures into another stage (schistosomula), then migrates to the lungs and liver, where it matures into the adult form. The adult worm then migrates to its preferred body part (bladder, rectum, intestines, liver, portal venous system (the veins that carry blood from the intestines to liver, spleen, lungs), depending on its species. Schistosomiasis is common in many tropical and subtropical areas worldwide. It can be treated safely and effectively with praziquantel.

MalaCards based summary : Schistosomiasis, also known as katayama fever, is related to intestinal schistosomiasis and urinary schistosomiasis. An important gene associated with Schistosomiasis is IL4 (Interleukin 4), and among its related pathways/superpathways are Innate Immune System and PEDF Induced Signaling. The drugs Lumefantrine and Artemether have been mentioned in the context of this disorder. Affiliated tissues include liver, testes and t cells, and related phenotypes are homeostasis/metabolism and cellular

Disease Ontology : 12 A parasitic helminthiasis infectious disease that involves infection of the intestine, urinary tract, skin, liver and spleen caused by multiple species of the trematode fluke of the genus Schistosoma. The symptoms include fever, chills, nausea, abdominal pain, diarrhea, malaise, myalgia, liver and spleen enlargement, rash and hematuria.

CDC : 3 Schistosomiasis, also known as bilharzia, is a disease caused by parasitic worms. Infection with Schistosoma mansoni, S. haematobium, and S. japonicum causes illness in humans; less commonly, S. mekongi and S. intercalatum can cause disease. Although the worms that cause schistosomiasis are not found in the United States, more than 200 million people are infected worldwide.

Wikipedia : 75 Schistosomiasis, also known as snail fever and bilharzia, is a disease caused by parasitic flatworms... more...

Related Diseases for Schistosomiasis

Diseases related to Schistosomiasis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 743)
# Related Disease Score Top Affiliating Genes
1 intestinal schistosomiasis 35.0 STAT6 IL5 IL4 IL13
2 urinary schistosomiasis 34.1 STAT6 RNASE3 IL5 IL4 IL13 IFNG
3 cytokine deficiency 31.7 IL5 IL13
4 portal hypertension 31.6 TNF GPT F2 ALB
5 paragonimiasis 31.6 RNASE3 IL5 IL13
6 filarial elephantiasis 31.4 IL5 IL4 IL10
7 strongyloidiasis 31.4 IL5 IL13 IFNG
8 hypereosinophilic syndrome 31.4 RNASE3 IL5 IL4 IL13 IGHE
9 appendicitis 31.3 TNF IL10 ALB
10 trichuriasis 31.1 TNF IL13 IL10
11 egg allergy 31.1 IL5 IL4 IGHE
12 ascaridiasis 31.1 IL13 IL10
13 fascioliasis 31.1 IL10 IFNG GPT ALB
14 hypersplenism 31.1 IFNG F2 ALB
15 echinococcosis 31.0 TNF IL5 IL10 IFNG
16 endomyocardial fibrosis 30.9 TNF IL4 IL10
17 hepatic coma 30.9 GPT F2 ALB
18 liver cirrhosis 30.9 SERPINF2 GPT F2 ALB
19 viral hepatitis 30.8 TNF GPT F2 ALB
20 radiculopathy 30.8 IL5 IL13 IL10
21 opisthorchiasis 30.7 TNF IL4 GPT
22 salmonellosis 30.7 IFNGR1 IFNG ALB
23 hepatitis b 30.7 TNF IFNG GPT F2 ALB
24 hepatic encephalopathy 30.7 TNF GPT F2 ALB
25 enterobiasis 30.7 IL5 IL4 IL13
26 dermatitis 30.6 IL5 IL4 IL13 IGHE IFNG
27 plasmodium falciparum malaria 30.6 TNF IL10 IFNG
28 allergic hypersensitivity disease 30.6 RNASE3 IL5 IL4 IL13 IL10 IGHE
29 liver disease 30.6 TNF GPT F2 ALB
30 toxoplasmosis 30.6 TNF IL4 IL10 IFNG CD40LG
31 pyelonephritis 30.6 TNF IL10 ALB
32 chlamydia 30.5 TNF IL4 IL10 IFNG
33 cholecystitis 30.5 GPT F2 ALB
34 tropical endomyocardial fibrosis 30.4 TNF IL4 IL10
35 eosinophilic pneumonia 30.4 RNASE3 IL5 IL13
36 poliomyelitis 30.3 TNF IL4 IL10 IFNG
37 meningitis 30.3 TNF IL10 IFNG ALB
38 clonorchiasis 30.3 TNF IL2 IL10 IFNG
39 protein-energy malnutrition 30.3 TNF GPT ALB
40 peritonitis 30.3 TNF IL10 F2 ALB
41 neuritis 30.2 TNF IL4 IFNG
42 idiopathic interstitial pneumonia 30.2 IL4 IL13 IFNG
43 buruli ulcer 30.2 IL4 IL10 IFNG CD40LG
44 uveitis 30.1 TNF IL4 IL10 IFNG
45 rheumatic disease 30.1 TNF IL10 IFNG CD40LG
46 rubella 30.1 TNF IL4 IL10 CD40LG
47 typhoid fever 30.1 TNF IFNGR1 IFNG F2 ALB
48 chagas disease 30.1 TNF IL2 IL10 IFNG
49 lung disease 30.0 TNF RNASE3 IL5 IL13 IL10
50 onchocerciasis 30.0 RNASE3 IL5 IL4 IL2 IL13

Graphical network of the top 20 diseases related to Schistosomiasis:



Diseases related to Schistosomiasis

Symptoms & Phenotypes for Schistosomiasis

MGI Mouse Phenotypes related to Schistosomiasis:

46 (show all 13)
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.3 ALB CD40LG F2 IFNG IFNGR1 IL10
2 cellular MP:0005384 10.26 ALB CD40LG IFNG IFNGR1 IL10 IL13
3 hematopoietic system MP:0005397 10.26 CD40LG F2 IFNG IFNGR1 IL10 IL13
4 digestive/alimentary MP:0005381 10.21 ALB F2 IFNG IFNGR1 IL10 IL13
5 immune system MP:0005387 10.21 CD40LG F2 IFNG IFNGR1 IL10 IL13
6 endocrine/exocrine gland MP:0005379 10.19 ALB CD40LG IFNG IFNGR1 IL10 IL13
7 liver/biliary system MP:0005370 10.07 ALB IFNG IFNGR1 IL10 IL2 IL4
8 integument MP:0010771 10.06 CD40LG F2 IFNG IFNGR1 IL10 IL13
9 neoplasm MP:0002006 9.92 ALB IFNG IFNGR1 IL10 IL2 IL5
10 reproductive system MP:0005389 9.9 CD40LG F2 IFNG IFNGR1 IL10 IL13
11 renal/urinary system MP:0005367 9.8 ALB CD40LG IFNG IFNGR1 IL4 LGMN
12 respiratory system MP:0005388 9.61 F2 IFNG IL10 IL13 IL2 IL4
13 skeleton MP:0005390 9.32 CD40LG F2 GPT IFNG IFNGR1 IL10

Drugs & Therapeutics for Schistosomiasis

Drugs for Schistosomiasis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 108)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Lumefantrine Approved Phase 4 82186-77-4 6437380
2
Artemether Approved Phase 4 71963-77-4 68911 119380
3 Artemether, Lumefantrine Drug Combination Phase 4
4
Myrrh Approved Phase 3 9000-45-7
5
Albendazole Approved, Vet_approved Phase 3 54965-21-8 2082
6
Sulfadoxine Approved, Investigational Phase 3 2447-57-6 17134
7
Pyrimethamine Approved, Investigational, Vet_approved Phase 3 58-14-0 4993
8
leucovorin Approved Phase 3 58-05-9 143 6006
9
Triclabendazole Approved, Investigational Phase 3 68786-66-3
10
Zinc sulfate Approved, Investigational Phase 2, Phase 3 7733-02-0
11
Zinc Approved, Investigational Phase 2, Phase 3 7440-66-6 32051
12
Amodiaquine Approved, Investigational Phase 3 86-42-0 2165
13
Tranexamic Acid Approved Phase 3 1197-18-8 5526
14
Mefloquine Approved, Investigational Phase 3 53230-10-7 4046
15
Artesunate Approved, Investigational Phase 3 88495-63-0 5464098 6917864
16
Folic acid Approved, Nutraceutical, Vet_approved Phase 3 59-30-3 6037
17
Dihydroartemisinin Experimental, Investigational Phase 3 71939-50-9 6918483
18
Piperaquine Experimental, Investigational Phase 3 4085-31-8 5079497
19 Iron Supplement Phase 3
20 Hematinics Phase 3
21 Ferric Compounds Phase 3
22 Micronutrients Phase 2, Phase 3
23 Trace Elements Phase 2, Phase 3
24 Tubulin Modulators Phase 3
25 Antimitotic Agents Phase 3
26 Fanasil, pyrimethamine drug combination Phase 3
27 Folic Acid Antagonists Phase 3
28 Renal Agents Phase 3
29 Sulfalene Phase 3
30 Vitamin B9 Phase 3
31 Vitamin B Complex Phase 3
32 Folate Phase 3
33 Anti-Infective Agents, Urinary Phase 3
34 Nutrients Phase 2, Phase 3
35 Dermatologic Agents Phase 2, Phase 3
36 Astringents Phase 2, Phase 3
37 Artemisinins Phase 3
38 Artemisinine Phase 3
39 Hemostatics Phase 3
40 Coagulants Phase 3
41 Antifibrinolytic Agents Phase 3
42 Antiprotozoal Agents Phase 3
43 Antimalarials Phase 3
44 Antiviral Agents Phase 3
45
Aluminum hydroxide Approved, Investigational Phase 1, Phase 2 21645-51-2
46
Sodium citrate Approved, Investigational Phase 1, Phase 2 68-04-2
47
Indian frankincense Approved, Experimental, Investigational Phase 1, Phase 2
48
Citric acid Approved, Nutraceutical, Vet_approved Phase 1, Phase 2 77-92-9 311
49
Calcium Approved, Nutraceutical Phase 1, Phase 2 7440-70-2 271
50
Imidazole Experimental, Investigational Phase 1, Phase 2 288-32-4 795

Interventional clinical trials:

(show top 50) (show all 86)
# Name Status NCT ID Phase Drugs
1 The Impact of Intermittent Preventive Malaria Treatment With Artemisinin Combination Therapy (ACT) on Hemoglobin, Malaria, Schistosomiasis, and School Attention Among Primary Schoolchildren in the Kassena-Nankana Districts, Ghana Unknown status NCT01459146 Phase 4 Artemether-lumefantrine combination plus albendazole;Artemether-lumefantrine plus Praziquantel plus Albendazole;Albendazole plus Praziquantel
2 Effect of Schistosomiasis Mansoni and Its Treatment on HIV Susceptibility and Female Genital Immunology Completed NCT02878564 Phase 4 Praziquantel
3 Evaluation of Praziquantel Dosage for Treatment of Schistosomiasis in Highly Endemic Areas of Northeastern Brazil Completed NCT00403611 Phase 4 Praziquantel 60 mg/kg;Praziquantel 40 mg/kg
4 Effect of Concomitant Mansonella Perstans Microfilaremia on Immune Responses Following Single Dose Praziquantel in Subjects With Schistosomiasis: A Pilot Study Withdrawn NCT02734186 Phase 4 Praziquantel
5 Efficacy of Chinese-made Versus WHO-PQ Praziquantel for Treatment of Schistosoma Haematobium in Zanzibar: a Randomized Controlled Trial Unknown status NCT03133832 Phase 3 Companion Tablet
6 Intravenous Ferric Carboxymaltose Compared With Oral Iron in the Treatment of Iron Deficiency Anemia at Delivery in Tanzania Unknown status NCT02541708 Phase 3 Ferric carboxymaltose;Ferrous sulfate + folic acid
7 Safety and Efficacy of Mirazid for Schistosomiasis Treatment as Compared to Praziquantel: An Open-label Randomized Non-placebo-Controlled Study Completed NCT01529710 Phase 3 Myrrh
8 Repeated Doses of Praziquantel in Schistosomiasis Treatment (RePST): An Open Label, Randomized Controlled Trial of Single vs. Multiple Treatments of Praziquantel in Intestinal African Schistosomiasis in Côte d'Ivoire Completed NCT02868385 Phase 3 4x Praziquantel;1x Praziquantel
9 Schistosoma Haematobium Infections Among Schoolchildren in Central Sudan One Year After Treatment With Praziquantel Completed NCT01558336 Phase 3 praziquantel
10 Efficacy and Safety Evaluation of the Therapeutic Vaccine Candidate Sh28GST in Association With Praziquantel (PZQ) for Prevention of Clinical and Parasitological Recurrences of S. Haematobium Infection in Children Completed NCT00870649 Phase 3
11 Open-label, Randomized Clinical Trial in Kenya to Determine the Effectiveness of Artesunate + Sulfamethoxypyrazine/Pyrimethamine Vs. Praziquantel in the Treatment of S. Mansoni in Children Completed NCT01054651 Phase 3 Artesunate+Sulfamethoxypyrazine/pyrimethamine;Praziquantel
12 Efficacy and Safety of Sulfadoxine-pyrimethamine or Sulfadoxine-pyrimethamine Plus Piperaquine Regimens Delivered Through Intermittent Preventive Treatment in Schoolchildren of Democratic Republic of Congo: A Randomised Control Trial Completed NCT01722539 Phase 3 Sulfadoxine-pyrimethamine;Piperaquine;Albendazole;Praziquantel
13 A Randomized, Double Blind, Controlled Study to Determine the Efficacy of Zinc Supplementation on Diarrhea Incidence in an Adult Population in Western Kenya. Completed NCT01166815 Phase 2, Phase 3
14 Prospective, Observational Study to Assess the Performance of CAA Measurement as a Diagnostic Tool for the Detection of Schistosoma Haematobium Infections in Pregnant Women and Their Newborn and Child in Lambaréné, Gabon Recruiting NCT03779347 Phase 3 Praziquantel
15 Effectiveness and Safety of Intermittent Preventive Treatment for Malaria Using Either Dihydroartemisinin-piperaquine or Artesunate-amodiaquine in Reducing Malaria Related Morbidities and Improving Cognitive Ability in School-aged Children in Tanzania: A Controlled Randomised Trial Recruiting NCT03640403 Phase 3 Dihydroartemisinin-piperaquine;Artesunate-amodiaquine
16 Tranexamic Acid for the Treatment of Gastrointestinal Haemorrhage: an International Randomised, Double Blind Placebo Controlled Trial Recruiting NCT01658124 Phase 3 Tranexamic Acid;Placebo
17 An Open Label, Phase III Efficacy and Safety Study of L Praziquantel Orodispersible Tablets (L-PZQ ODT) in Schistosoma Infected Children 3 Months to 6 Years of Age, Including a 2:1 Randomized, Controlled Cohort of Schistosoma Mansoni Infected Children 4 to 6 Years of Age Treated With L PZQ ODT or Commercial PZQ (Biltricide®) Not yet recruiting NCT03845140 Phase 3 L-PZQ ODT;Biltricide®;L-PZQ ODT
18 A Proof-of-concept Trial to Evaluate Artesunate-mefloquine as a Novel Alternative Treatment for Schistosomiasis in African Children Not yet recruiting NCT03893097 Phase 3 Praziquantel;Artesunate + Mefloquine
19 Safety and Efficacy of a Novel Candidate Peptide Vaccine Against HCV Infection in Healthy Volunteers and in Treated (Non-responders/ Responders) Chronic HCV Patients. Clinical Trials Phases I and II Unknown status NCT01718834 Phase 1, Phase 2
20 Intestinal Schistosomiasis in Children Aged 1-5 Years,Morbidity Assessment and the Effect of Praziquantel on Morbidity; Along Lake Victoria Shorelines. Completed NCT01901484 Phase 2 Praziquantel
21 A Phase II Open Label Trial to Investigate the Effect of Schistosoma Mansoni (Sm) Infection on the Immunogenicity of a Candidate TB Vaccine, MVA85A, in BCG-vaccinated African Adolescents Completed NCT02178748 Phase 2
22 Activity of Mefloquine Against Urinary Schistosomiasis Completed NCT01132248 Phase 2 Mefloquine;S/P
23 Open-label, Dose-finding, 2-parts, Efficacy Phase II Study With Three Formulations (Racemate Raziquantel Commercial Oral Tablets, New Oral Disintegrating Tablets of Racemate Praziquantel and L-praziquantel) in Schistosomiasis (S. Mansoni) Infected Children Aged 2-6 Years (Part 1), Followed by an Assessment of Efficacy and Safety With the Selected Formulation and Dosage in S. Mansoni Infected Infants Aged 3-24 Months (Part 2) Completed NCT02806232 Phase 2 Biltricide (racemate praziquantel) oral tablets;Racemate Praziquantel ODT;Levo Praziquantel ODT
24 S. Japonicum and Pregnancy Outcomes: A Randomized, Double Blind, Placebo Controlled Trial (RCT) Completed NCT00486863 Phase 2 Praziquantel
25 Safety and Immunogenicity Evaluation of the Vaccine Candidate Sm14 in Combination With the Adjuvant Glucopyranosyl Lipid A (GLA-SE) in Adults Living in Endemic Regions for S. Mansoni and S. Haematobium in Senegal. A Comparative, Randomized, Open-label Trial Completed NCT03041766 Phase 2 GLA-SE solution
26 Safety and Immunogenicity Evaluation of the Vaccine Candidate Sm14 Against Schistosomiasis in Senegalese School Children Healthy or Infected With S. Mansoni and/or S. Haematobium. A Comparative, Randomized, Controlled, Open-label Trial Active, not recruiting NCT03799510 Phase 2 GLA-SE solution
27 Phase II PK/PD Driven Dose Finding Trial of Praziquantel in Children Under Four Not yet recruiting NCT03640377 Phase 2 Praziquantel
28 A Phase I/II Trial of the Safety, Immunogenicity, and Efficacy of the Sm-TSP-2/Alhydrogel® Schistosomiasis Vaccine in Healthy Exposed Ugandan Adults Not yet recruiting NCT03910972 Phase 1, Phase 2
29 Treatment of Renal Stones With Frankincense (Boswellic Acid): A Clinical Randomized Trial Not yet recruiting NCT03924596 Phase 1, Phase 2 AKBA-Incense (3-acetyl-11-keto-ß-boswellic acid);Potassium Sodium Hydrogen Citrate
30 A Phase I Study of the Safety, Reactogenicity, and Immunogenicity of Sm-TSP-2/Alhydrogel® With or Without GLA-AF for Intestinal Schistosomiasis in Healthy Adults Completed NCT02337855 Phase 1
31 A Phase I Double Blind Placebo-controlled Clinical Trial to Evaluate the Safety and Immunogenicity of the Combination of DNA-HIV-PT123 and AIDSVAX®B/Ein HIV-1-uninfected Adult Participants With or Without Underlying Schistosoma Mansoni Infection Completed NCT02376582 Phase 1
32 Phase 1 Study Evaluating Safety and Immunological Criteria of Efficacy of the Recombinant Vaccine Candidate Bilhvax Against Schistosomiasis Completed NCT01512277 Phase 1
33 Praziquantel Pharmacokinetics in Pregnancy and During Lactation Completed NCT01288872 Phase 1 Praziquantel
34 Phase 1 Study to Evaluate the Safety of the Vaccine Prepared sm14 Against Schistosomiasis Completed NCT01154049 Phase 1
35 Group A Streptococcal Human Challenge Study: Building a Pharyngitis Model to Accelerate Vaccine Development Recruiting NCT03361163 Phase 1
36 A Phase Ib Study of the Safety, Reactogenicity, and Immunogenicity of Sm-TSP-2/Alhydrogel(R) With or Without AP 10-701 for Intestinal Schistosomiasis in Healthy Exposed Adults Active, not recruiting NCT03110757 Phase 1
37 Study on the Role of Antioxidant Micronutrients on the Reversal of Schistosomal Peri-portal Fibrosis of the Liver. Unknown status NCT01260012
38 Association of Schistosomiasis Seropositivity With Adverse Birth Events in Migrants From Bilharzia-endemic Areas Unknown status NCT03158298
39 Evaluation of Strategies for Improved Uptake of Preventive Treatment for Intestinal Schistosomiasis Among School Children in Jinja District, Uganda: a Stratified Cluster Randomized Controlled Trial Unknown status NCT01869465
40 Epidemiology of Human Immunodeficiency Virus (HIV-1) and Schistosoma Mansoni Co-infections and Its Impact on Anthelminthic Treatment Outcome Among HIV-1 Infected Individuals in Fishing Communities in Mwanza Region, Northwestern Tanzania. Unknown status NCT01541631 Praziquantel and Albendazole;Praziquantel and Albendazole;Praziquantel and Albendazole
41 The Evaluation of Glycyrrhizic Acid's Pesticide Effect in Treating Liver Damage (Retrospective Study) Unknown status NCT02329314
42 ANRS 12320 IMMHoTHep : Investigative Mathematical Modeling of Hospital Transmission of Hepatitis C Unknown status NCT02826447
43 Evaluation of Applicability of Urine Based Schistosomiasis Test Strip in the Epidemiologic Mapping and Sampling of Schistosoma Mansoni Infection in Low Endemic Areas of Kenya Completed NCT00463307
44 Effects of Arachidonic Acid Supplementation on Schistosomiasis Mansoni Infection in Egyptian School Children Completed NCT02144389 Praziquantel (PZQ)
45 Treatment of Schistosomal Portal Hypertension: Assessment of Efficacy of Endoscopic Therapy Alone or in the Combined With Surgical Procedure Completed NCT01931826
46 Village Surveys of Morbidity Due to S. Haematobium for 1U01AI4547 Urinary Schistosomiasis-Determinants of Infection and Disease Completed NCT00138450
47 Establishing a Single-sex Controlled Human Schistosomiasis Infection Model: Safety and Dose Finding Completed NCT02755324
48 Comparison of Schistosomiasis Diagnostic Techniques and Study of Schistosoma Infection on Children's Immune Response to Childhood Vaccines, on Anaemia and on Nutritional Status Completed NCT01553552
49 Assessment of Anaemia Attributable to Schistosomiasis in School Children in Kenya: Mechanisms and Effect of Treatment Completed NCT00414479 praziquantl, iron, ACT
50 Iron Supplementation in Schistosomiasis and Soil Transmitted Helminths Control Programmes in Zambia Completed NCT00276224 ferrous sulphate (drug)

Search NIH Clinical Center for Schistosomiasis

Inferred drug relations via UMLS 72 / NDF-RT 51 :


Oxamniquine
Praziquantel
Praziquantel

Cochrane evidence based reviews: schistosomiasis

Genetic Tests for Schistosomiasis

Anatomical Context for Schistosomiasis

MalaCards organs/tissues related to Schistosomiasis:

41
Liver, Testes, T Cells, Spleen, Skin, Colon, Spinal Cord

Publications for Schistosomiasis

Articles related to Schistosomiasis:

(show top 50) (show all 15703)
# Title Authors PMID Year
1
Arginase I suppresses IL-12/IL-23p40-driven intestinal inflammation during acute schistosomiasis. 9 38
20483789 2010
2
Transforming growth factor-beta and Th17 responses in resistance to primary murine schistosomiasis mansoni. 9 38
19717308 2009
3
[The role of TGFbeta1 and IL-13 in cellular signal transduction of hepatic fibrosis of schistosomiasis]. 9 38
20066997 2009
4
Antioxidant status and lipid peroxidation activity in evaluating hepatocellular damage in children. 9 38
20187535 2009
5
Immunoglobulin E (IgE) responses to paramyosin predict resistance to reinfection with Schistosoma japonicum and are attenuated by IgG4. 9 38
19273558 2009
6
Circulating CD23+ B cell subset correlates with the development of resistance to Schistosoma mansoni reinfection in occupationally exposed adults who have undergone multiple treatments. 9 38
19072134 2009
7
Association of the gene polymorphisms IFN-gamma +874, IL-13 -1055 and IL-4 -590 with patterns of reinfection with Schistosoma mansoni. 9 38
19190772 2009
8
Genetic polymorphism of glutathione-S-transferase (GST-M1 and GST-T1) in schistosomiasis -associated bladder cancer in Egyptian patients. 9 38
19209780 2008
9
IL-4 and reactive oxygen species are elevated in Egyptian patients affected with schistosomal liver disease. 9 38
19067841 2008
10
Cytokines, chemokine receptors, CD4+CD25HIGH+ T-cells and clinical forms of human schistosomiasis. 9 38
18534548 2008
11
Discriminating acute from chronic human schistosomiasis mansoni. 9 38
18851939 2008
12
Eosinophil activation status, cytokines and liver fibrosis in Schistosoma mansoni infected patients. 9 38
18550021 2008
13
Eosinophil cationic protein, soluble egg antigen, circulating anodic antigen, and egg excretion in male urogenital schistosomiasis. 9 38
18784236 2008
14
Schistosomiasis and infection with human immunodeficiency virus 1 in rural Zimbabwe: systemic inflammation during co-infection and after treatment for schistosomiasis. 9 38
18784223 2008
15
Cytokine profile associated with chronic and acute human schistosomiasis mansoni. 9 38
18949326 2008
16
sTNFR-II and sICAM-1 are associated with acute disease and hepatic inflammation in schistosomiasis japonica. 9 38
18001742 2008
17
Proteases from Schistosoma mansoni cercariae cleave IgE at solvent exposed interdomain regions. 9 38
17631966 2008
18
Treatment of human acute schistosomiasis with oxamniquine induces an increase in interferon-gamma response to Schistosoma mansoni antigens. 9 38
17426890 2007
19
Schistosome membrane proteins as vaccines. 9 38
17222846 2007
20
Changes in the humoral immune responses after chemotherapy in single and co-infected individuals with Schisosoma haematobium and Plasmodium falciparum. 9 38
20353134 2006
21
The role of chemokines in Schistosoma mansoni infection: insights from human disease and murine models. 9 38
17308793 2006
22
Cloning the genes and DNA binding properties of High Mobility Group B1 (HMGB1) proteins from the human blood flukes Schistosoma mansoni and Schistosoma japonicum. 9 38
16644144 2006
23
Skin test reactivity and Der p-induced interleukin 10 production in patients with asthma or rhinitis infected with Ascaris. 9 38
16729785 2006
24
Some molecular aspects in schistosomiasis mansoni and toxoplasmosis. 9 38
16333889 2005
25
De-glycosylation of Pichia pastoris-produced Schistosoma mansoni cathepsin B eliminates non-specific reactivity with IgG in normal human serum. 9 38
16125194 2005
26
Detection of IgG binding to Schistosoma mansoni recombinant protein RP26 is a sensitive and specific method for acute schistosomiasis diagnosis. 9 38
15710554 2005
27
Human T cell epitope mapping of the Schistosoma mansoni 14-kDa fatty acid-binding protein using cells from patients living in areas endemic for schistosomiasis. 9 38
15725385 2005
28
Interleukin (IL)-4, IL-10, IL-18 and IFN-gamma cytokines pattern in patients with combined hepatitis C virus and Schistosoma mansoni infections. 9 38
15644127 2005
29
Production of interferon-gamma by natural killer cells and aging in chronic human schistosomiasis. 9 38
15770048 2004
30
Interleukin-13 in the skin and interferon-gamma in the liver are key players in immune protection in human schistosomiasis. 9 38
15361241 2004
31
[The clinical significance of interferon-gamma and its receptor in patients with schistosomiasis]. 9 38
15830877 2004
32
HTLV-1 modifies the clinical and immunological response to schistosomiasis. 9 38
15270862 2004
33
Chemotherapy for schistosomiasis in Ugandan fishermen: treatment can cause a rapid increase in interleukin-5 levels in plasma but decreased levels of eosinophilia and worm-specific immunoglobulin E. 9 38
15213147 2004
34
Schistosoma mansoni PIII antigen modulates in vitro granuloma formation by regulating CD28, CTLA-4, and CD86 expression in humans. 9 38
15019278 2004
35
Different cytokine patterns in patients coinfected with hepatitis C virus and Schistosoma mansoni. 9 38
15724383 2004
36
Clinical and immunological consequences of human T cell leukemia virus type-I and Schistosoma mansoni co-infection. 9 38
15486648 2004
37
Immunoblot analysis of Schistosoma japonicum egg antigens with sera from patients with acute and chronic schistosomiasis japonica. 9 38
15115074 2003
38
IFN-gamma polymorphisms (IFN-gamma +2109 and IFN-gamma +3810) are associated with severe hepatic fibrosis in human hepatic schistosomiasis (Schistosoma mansoni). 9 38
14607968 2003
39
Assessment of eosinophil cationic protein as a possible diagnostic marker for female genital schistosomiasis in women living in a Schistosoma haematobium endemic area. 9 38
15053779 2003
40
Malaria co-infection in children influences antibody response to schistosome antigens and inflammatory markers associated with morbidity. 9 38
15228260 2003
41
Enhanced interleukin-12 and CD40 ligand activities but reduced Staphylococcus aureus Cowan 1-induced responses suggest a generalized and progressively impaired type 1 cytokine pattern for human schistosomiasis. 9 38
12379664 2002
42
P38 mitogen-activated protein kinase influence on the production of IL-10 in human schistosomiasis mansoni. 9 38
12654092 2002
43
Assessing the morbidity of schistosomiasis by measuring eosinophil cationic protein in serum. 9 38
12214929 2002
44
Polarized Th2 like cells, in the absence of Th0 cells, are responsible for lymphocyte produced IL-4 in high IgE-producer schistosomiasis patients. 9 38
12100735 2002
45
Description of three new polymorphisms in the intronic and 3'UTR regions of the human interferon gamma gene. 9 38
11857052 2002
46
IgG anti-IgE autoantibodies in visceral leishmaniasis. 9 38
11992157 2002
47
Performance of IgG avidity in an area endemic for schistosomiasis in Egypt. 9 38
15330573 2002
48
Clinical and immunologic evaluation of 31 patients with acute schistosomiasis mansoni. 9 38
11756987 2002
49
Studies on the production and regulation of interleukin, IL-13, IL-4 and interferon-gamma in human Schistosomiasis mansoni. 9 38
12426605 2002
50
Immunoglobulin-E and anti-IgE treatment in lung disease. 9 38
11980283 2001

Variations for Schistosomiasis

Expression for Schistosomiasis

Search GEO for disease gene expression data for Schistosomiasis.

Pathways for Schistosomiasis

Pathways related to Schistosomiasis according to GeneCards Suite gene sharing:

(show top 50) (show all 57)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.08 TNF STAT6 RNASE3 LGMN IL5 IL4
2
Show member pathways
13.72 TNF IL5 IL4 IL2 IL13 IL10
3
Show member pathways
13.6 TNF STAT6 IL5 IL4 IL2 IL13
4
Show member pathways
13.45 TNF STAT6 IL5 IL4 IL2 IL13
5
Show member pathways
13.42 TNF STAT6 IL5 IL4 IL2 IL13
6
Show member pathways
13.33 TNF IL5 IL4 IL2 IL13 IL10
7 12.91 STAT6 IL5 IL4 IL2 IL13 IFNGR1
8
Show member pathways
12.8 TNF RNASE3 LGMN IL5 IL4 IL2
9
Show member pathways
12.71 TNF IL4 IL2 IL10 IGHE IFNGR1
10
Show member pathways
12.67 TNF STAT6 IL2 IL10 IFNG F2
11
Show member pathways
12.66 TNF IL5 IL4 IL2 IL10 IFNG
12 12.65 TNF STAT6 IL4 IL2 IL10 IFNG
13
Show member pathways
12.62 TNF IL5 IL4 IL13 IGHE
14
Show member pathways
12.56 TNF IL4 IL2 IFNGR1 IFNG
15
Show member pathways
12.56 TNF STAT6 IL5 IL4 IL2 IL13
16
Show member pathways
12.44 STAT6 IL5 IL4 IL2 IL13 IL10
17
Show member pathways
12.43 TNF IL4 IL2 IFNG F2 ALB
18
Show member pathways
12.4 TNF IL5 IL4 IL13 IFNG
19
Show member pathways
12.36 TNF IL4 IL10 IFNGR1 IFNG CD40LG
20
Show member pathways
12.35 TNF IL5 IL4 IL2 IL13 IL10
21 12.27 TNF IL10 IFNGR1 IFNG
22
Show member pathways
12.25 TNF STAT6 IFNGR1 IFNG
23
Show member pathways
12.22 TNF IL4 IFNGR1 IFNG
24 12.21 TNF IL13 IL10 GAPDH
25
Show member pathways
12.17 IL5 IL4 IL2 IL13 IL10 IFNGR1
26
Show member pathways
12.15 TNF IL2 IL10 IFNGR1 IFNG
27
Show member pathways
12.13 TNF IL4 IL13 IFNG F2
28 12.1 TNF IL5 IL4 IL2 IL10 IFNG
29 12.07 TNF IL4 IL2 IFNG
30 12.07 TNF STAT6 IL4 IL13 IL10 IGHE
31
Show member pathways
12.04 STAT6 IL4 IL2 IFNG
32 11.97 STAT6 IL2 IL10 IFNGR1 IFNG
33 11.92 IL5 IL4 IL2 IL13 IFNG
34 11.9 TNF IL10 IFNG
35 11.88 TNF IL5 IL4
36 11.84 TNF IL2 IL10 IFNG
37
Show member pathways
11.81 TNF IL5 IL4 IL2 IFNG CD40LG
38
Show member pathways
11.76 TNF IL2 IFNG CD40LG
39 11.76 TNF IL5 IL4 IL13
40 11.76 TNF IL4 IL2 IL13 IL10 IFNG
41 11.7 TNF IL5 IL4 IL2 IL13 IL10
42
Show member pathways
11.68 TNF IL2 IFNG
43 11.68 STAT6 IL5 IL4 IL10 IGHE CD40LG
44 11.64 TNF IL10 IFNG CD40LG
45 11.63 TNF IL4 IL13 IL10
46 11.59 TNF IL2 IFNG
47
Show member pathways
11.58 TNF IFNGR1 IFNG
48 11.56 TNF IL2 IFNG
49 11.44 TNF IL10 IFNG
50 11.43 IL5 IL4 IL2 IFNG CD40LG

GO Terms for Schistosomiasis

Cellular components related to Schistosomiasis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.8 TNF SERPINF2 RNASE3 LGMN IL5 IL4
2 external side of plasma membrane GO:0009897 9.55 TNF IL13 IGHE F2 CD40LG
3 extracellular space GO:0005615 9.44 TNF SERPINF2 RNASE3 IL5 IL4 IL2

Biological processes related to Schistosomiasis according to GeneCards Suite gene sharing:

(show all 33)
# Name GO ID Score Top Affiliating Genes
1 inflammatory response GO:0006954 9.95 TNF IL5 IL13 IL10 CD40LG
2 defense response to bacterium GO:0042742 9.93 TNF RNASE3 IL10 IGHE
3 positive regulation of protein phosphorylation GO:0001934 9.87 TNF IL2 IFNG F2
4 positive regulation of cold-induced thermogenesis GO:0120162 9.83 STAT6 IL4 IL13
5 response to organic substance GO:0010033 9.82 TNF SERPINF2 IL10
6 B cell differentiation GO:0030183 9.79 IL4 IL10 CD40LG
7 antimicrobial humoral immune response mediated by antimicrobial peptide GO:0061844 9.78 RNASE3 GAPDH F2
8 positive regulation of T cell proliferation GO:0042102 9.77 IL4 IL2 CD40LG
9 positive regulation of smooth muscle cell proliferation GO:0048661 9.75 TNF SERPINF2 IL13
10 negative regulation of endothelial cell apoptotic process GO:2000352 9.67 IL4 IL13 IL10
11 cellular response to hepatocyte growth factor stimulus GO:0035729 9.65 LGMN IL10
12 regulation of interferon-gamma-mediated signaling pathway GO:0060334 9.64 IFNGR1 IFNG
13 positive regulation of podosome assembly GO:0071803 9.64 TNF IL5
14 positive regulation of immunoglobulin secretion GO:0051024 9.63 IL5 IL2
15 positive regulation of isotype switching to IgG isotypes GO:0048304 9.62 IL4 IL2
16 negative regulation of fibrinolysis GO:0051918 9.62 SERPINF2 F2
17 immune response GO:0006955 9.61 TNF IL5 IL4 IL2 IL13 IL10
18 endothelial cell apoptotic process GO:0072577 9.6 TNF IL10
19 positive regulation of MHC class II biosynthetic process GO:0045348 9.58 IL4 IL10
20 negative regulation of cytokine secretion involved in immune response GO:0002740 9.56 TNF IL10
21 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.56 IL4 IL2 IL13 IFNG
22 regulation of immunoglobulin secretion GO:0051023 9.54 TNF CD40LG
23 positive regulation of cytokine secretion GO:0050715 9.54 TNF IL10 GAPDH
24 type 2 immune response GO:0042092 9.52 IL4 IL10
25 regulation of isotype switching GO:0045191 9.51 IL4 IL10
26 receptor biosynthetic process GO:0032800 9.48 TNF IL10
27 positive regulation of isotype switching to IgE isotypes GO:0048295 9.46 STAT6 IL4
28 positive regulation of B cell proliferation GO:0030890 9.46 IL5 IL4 IL2 IL13
29 positive regulation of calcidiol 1-monooxygenase activity GO:0060559 9.43 TNF IFNG
30 negative regulation of complement-dependent cytotoxicity GO:1903660 9.4 IL4 IL13
31 positive regulation of vitamin D biosynthetic process GO:0060557 9.32 TNF IFNG
32 cytokine-mediated signaling pathway GO:0019221 9.28 TNF STAT6 IL5 IL4 IL2 IL13
33 positive regulation of cell proliferation GO:0008284 10.06 LGMN IL5 IL2 IFNG F2

Molecular functions related to Schistosomiasis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 growth factor activity GO:0008083 9.35 IL5 IL4 IL2 IL10 F2
2 cytokine activity GO:0005125 9.23 TNF IL5 IL4 IL2 IL13 IL10

Sources for Schistosomiasis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....